文献速递淋巴瘤

滤泡性淋巴瘤中的染色质修饰基因突变

Chromatin modifying gene mutations in follicular lymphoma.
PubMed 文献 · Blood · 2017-11-20

本文综述滤泡性淋巴瘤中染色质修饰基因突变的现有认识。二代测序将染色质修饰基因突变确定为该病标志,最常突变者为KMT2D、CREBBP和EZH2,这些事件改变正常B细胞分化程序并阻碍生发中心退出。多数肿瘤连续获得多个染色质修饰基因突变,提示其间交互或协同尚未明确;作者讨论其治疗靶点潜力及未来值得探索的方向。

要点

  • 染色质修饰基因突变是滤泡性淋巴瘤的标志,二代测序研究已将其确定为该病特征。
  • 最常突变的染色质修饰基因为KMT2D、CREBBP和EZH2,其功能后果已获新认识。
  • 这些突变改变正常B细胞分化程序并阻碍生发中心退出,染色质修饰酶为有吸引力的治疗靶点。

核心结论

  • 染色质修饰基因突变是滤泡性淋巴瘤的标志,染色质修饰酶是该病有吸引力的治疗靶点。
  • 理解这些突变的复杂作用对识别和适应性靶向相关脆弱性至关重要。
  • 多数滤泡性淋巴瘤肿瘤连续获得多个染色质修饰基因突变,提示事件间存在尚未明确的交互或协同。
  • 作者认为未来应考虑尚未探索的领域。

研究设计与样本

  • 本文为综述,总结滤泡性淋巴瘤中染色质修饰基因突变的现有知识。
  • 综述基于二代测序研究,讨论染色质修饰基因突变作为治疗靶点的潜力。

主要发现

  • 滤泡性淋巴瘤患者总生存近期随新疗法引入而改善,但患者结局存在显著异质性。
  • 最常突变的染色质修饰基因为KMT2D、CREBBP和EZH2,近期研究提供了其功能后果的见解。
  • 这些事件改变正常B细胞分化程序并阻碍生发中心退出。
  • 多数滤泡性淋巴瘤肿瘤连续获得多个染色质修饰基因突变,提示事件间交互或协同尚未明确。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 多数滤泡性淋巴瘤肿瘤连续获得多个染色质修饰基因突变,提示事件间存在尚未明确的交互或协同。
  • 作者提出未来应考虑尚未探索的领域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma (FL) is an indolent malignancy of germinal center B cells. Although the overall survival of FL patients has recently improved with the introduction of novel therapies, there is significant heterogeneity in patient outcome and a need for rationally designed therapeutic strategies that target disease biology. Next-generation sequencing studies have identified chromatin modifying gene (CMG) mutations as a hallmark of FL, highlighting epigenetic modifiers as an attractive therapeutic target in this disease. Understanding the complex roles of these mutations will be central to identifying and adaptively targeting associated vulnerabilities. Recent studies have provided insight into the functional consequences of the most frequently mutated CMGs (KMT2D, CREBBP, and EZH2) and point to a role for these events in modifying normal B-cell differentiation programs and impeding germinal center exit. However, the majority of FL tumors serially acquire multiple CMG mutations, suggesting that there is a level of cross talk or cooperation between these events that has not yet been defined. Here, I review the current state of knowledge on CMG mutations in FL, discuss their potential as therapeutic targets, and offer my perspective on unexplored areas that should be considered in the future.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood. 2017. PMID: 29158360. doi:10.1182/blood-2017-08-737361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。